SUPERNUS PHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

SUPERNUS PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $718.95 million for the year ending 2025.

  • SUPERNUS PHARMACEUTICALS, INC. showed an increase of +8.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 75.8%.
  • Historical annual values: Fiscal year 2025: $718.95 million | Fiscal year 2024: $661.82 million | Fiscal year 2023: $607.52 million | Fiscal year 2022: $667.24 million | Fiscal year 2021: $579.78 million | Fiscal year 2020: $520.40 million | Fiscal year 2019: $392.76 million | Fiscal year 2018: $408.90 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: